Hormonothérapie dans le cancer du sein invasif, update 2016 [Hormone therapy in invasive breast cancer : update 2016]

Détails

ID Serval
serval:BIB_50C445402734
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Hormonothérapie dans le cancer du sein invasif, update 2016 [Hormone therapy in invasive breast cancer : update 2016]
Périodique
Revue medicale suisse
Auteur(s)
Zurcher J.P., Stravodimou A., Zaman K.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
21/09/2016
Peer-reviewed
Oui
Volume
12
Numéro
531
Pages
1580-1583
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Invasive breast cancer is the most common malignancy in women in industrialized countries. Three-quarters of breast cancers express estrogen and/or progesterone receptors and are considered endocrine-sensitive. Endocrine therapy reduces the risk of loco-regional, contralateral and distant recurrence. The management has become more complex with estrogen receptor inhibitors, aromatase inhibitors and ovarian function suppression. The choice of the regimen and its duration depend on the age, the menopausal status of the patient, her co-morbidities, the risk of cancer relapse and the tolerance. We summarize here the recent modifications of the endocrine therapy in early and advanced stage breast cancer.

Mots-clé
Age Factors, Antineoplastic Agents, Hormonal/pharmacology, Antineoplastic Agents, Hormonal/therapeutic use, Aromatase Inhibitors/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Estrogen Receptor Antagonists/therapeutic use, Female, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Receptors, Estrogen/genetics, Receptors, Progesterone/genetics
Pubmed
Création de la notice
10/07/2017 17:07
Dernière modification de la notice
02/10/2018 6:26
Données d'usage